SAGE Working Group on hepatitis A vaccine (March 2010 to July 2012)
Terms of Reference
The Working Group will be asked to review the evidence with respect to the following questions/issues and to propose to SAGE recommendations, including the need to update recommendations stated in the current (2000) hepatitis A vaccine position paper:
- Review data regarding the global prevalence and burden of disease caused by hepatitis A virus infection.
- Review position paper recommendations regarding when countries should consider introduction of hepatitis A vaccine.
- Review issues related to establishment of regional or global hepatitis A control goals.
- Outline aspects of a comprehensive strategy for hepatitis A control.
- Review issues related to hepatitis A surveillance
- Identify additional critical issues that need to be considered in updating, referencing and providing evidence grading for the current hepatitis A vaccine position paper.
Composition
SAGE Members
- Art Reingold, Chair. University of California, United States of America
- Xiaofeng Liang, Chinese Center for Disease Control and Prevention, China
Experts
- Jeffrey Mphahlele, University of Limpopo, South Africa
- John W. Ward, Centers for Disease Control and Prevention, USA
- Marta Vacchino, National Institute of Epidemiology, Argentina
- Andrew Hall, London School of Hygiene and Tropical Medicine, UK
- Daniel Shouval, Hadassah Hebrew University Hospital, Israel
WHO Secretariat
- Steven Wiersma
DECLARATION OF INTERESTS FOR WHO EXPERTS
All members completed a declaration of interest. Only one member reported any direct interests and these interests were assessed as not relevant to the work of the Working Group.
Professor Jeffrey Mphahlele:
• His Centre receives funding from Sanofi Pasteur and Biovac SA Pty for maintenance of its website.
Last updated: 6 August 2012